

Medical Benefit Pharmacy Prior Approval List

Updated 07/01/2025

The following medications require Prior Approval. The medications are processed through the medical benefit. There may be additional medications that are handled through the Pharmacy Benefit. Please review the appropriate pharmacy benefit for complete Prior Approval list.

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product
Abecma	idecabtagene vicleucel	Q2055	AR 2024041	8/1/2021		
Actemra IV	tocilizumab IV	J3262	AR 2020022	4/1/2022		
Acthar	corticotropin	J0801	AR 2013048	12/1/2023		
Adakveo	crizanlizumab-tcma	J0791	AR 2020011	2/1/2020		
Adstiladrin	nadofaragene firadenovec-vncg	J9029	AR 2023020	5/24/2023		
Adzynma	ADAMTS13, recombinant-krhn	J7171	AR 2024020	6/19/2024		
Ahzantive	afilbercept-mrbb	Q5150	AR 2024066	3/12/2025		Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Cimerli (Q5128), Eylea HD (J0177) or Eylea (J0178) preferred]
Aldurazyme	laronidase	J1931	AR 2018025	9/1/2018		
Alymsys	bevacizumab-maly	Q5126	AR 2017006 & AR 2023014	01/01/2024 - NOT PA'd for OPTHALMIC indications		Non-preferred [Mvasi (Q5107) & Zirabev (Q5118) preferred]
Amtagvi	lifileucel	J9999	AR 2024019	7/1/2024		
Amvuttra	vutrisiran	J0225	AR 2022042	11/9/2022		
Anktiva	nogapendekin alfa inbakicept-pmln	J9028	AR 2024072	11/7/2024		
Aralast NP	alpha-1 proteinase inhibitor (human)	J0256	AR 2017001	9/1/2023		
Arcalyst	rilonacept	J2793	AR 2008031	10/1/2021		



Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product
Asparlas	calaspargase pegol	J9118	AR 2022019	8/1/2022		
Aucatzyl	obecabtagene autoleucel	Q2058	AR 2025004	2/26/2025		
Avastin	bevacizumab	J9035	AR 2017006 & AR 2023014	01/01/2024 - NOT PA'd for OPHTHALMIC indications		Non-preferred [Mvasi (Q5107) & Zirabev (Q5118) preferred]
Avsola	infliximab-axxq	Q5121	AR 1998161	4/1/2022		Non-preferred [Inflectra (Q5103), Infliximab (J1745), Remicade (J1745) preferred]
Benlysta IV	belimumab IV	J0490	AR 2021033	10/1/2021		
Beovu	brolocizumab-dblI	J0179	AR 2024066	1/1/2025		Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Cimerli (Q5128), Eylea HD (J0177) or Eylea (J0178) preferred]
Beqvez	fidanacogene elaparvovec-dzkt	J1414	AR 2024067	9/1/2024		
Berinert	c1 esterase, inhibitor, human	J0597	AR 2013032	6/1/2018		
Bizengri	zenocutuzumab-zbco	J9382	AR 2025009	4/23/2025		
Bkemv	eculizumab-aeeb	Q5152	AR 2016013	4/23/2025		Non-preferred [Soliris (J1299) preferred]
Blinicyto	blinatumomab	J9039	AR 2016009	10/11/2023		
Botox	onabotulinumtoxin a	J0585	AR 2018002 & AR 2000034	4/1/2022		
Breyanzi	lisocabtagene maraleucel	Q2054	AR 2024042	5/1/2021		
Brineura	cerliponase alfa	J0567	AR 2017022	4/1/2018		
Briumvi	ublituximab-siiy	J2329	AR 2023041	10/1/2023		
Cablivi	caplacizumab-yhdp	C9047	AR 2019006	8/1/2019		
Carvykti	ciltacabtagene autoleucel	Q2056	AR 2024040	6/1/2022		
Casgevy	exagamglogene autotemcel	J3392	AR 2024013	5/29/2024		
Cerezyme	imiglucerase	J1786	AR 2023048	2/1/2024		
Cimzia	certolizumab pego	J0717	AR 2024037	12/1/2024		
Cinqair	reslizumab	J2786	AR 2018008	6/1/2018		

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product
Cinryze	c1 esterase, inhibitor, human	J0598	AR 2013032	6/1/2018		
Columvi	glofitamab-gxbm	J9286	AR 2023036	8/2/2023		
Cosela	trilaciclib	J1448	AR 2021046	4/23/2025		
Cosentyx IV	secukinumab IV	J3247	AR 2024016	5/29/2024		
Crysvita	burosumab-twza	J0584	AR 2018024	9/1/2018		
Danyelza	naxitamab-gqgk	J9348	AR 2021017	2/28/2024		
Datroway	datopotamab deruxtecan-dlnk	J9999	AR 2025007	3/12/2025		
Daxxify	daxibotulinumtoxina-lanm	J0589	AR 2018002	2/28/2024		
Duopa	levodopa-carbidopa intestinal gel	J7340	AR 2018023	9/1/2018		
Dysport	abobotulinumtoxin a	J0586	AR 2018002	4/1/2022		
Elahere	mirvetuximab soravtansine-gynx	J9063	AR 2023019	5/17/2023		
Elaprase	idursulfase	J1743	AR 2018025	9/1/2018		
Elelyso	taliglucerase alfa	J3060	AR 2023048	2/1/2024		
Elevidys	delandistrogene moxeparvover-rold	J1413				
Elfabrio	pegunigalsidase alfa-iwxj	J2508	AR 2023013	8/2/2023		
Elrexio	elranatamab-bcmm	J1323	AR 2024006	3/6/2024		
Elzonris	tagrazofusp-erzs	J9269	AR 2020012	8/1/2019		
Enjaymo	sutimlimab-jome	J1302	AR 2022024	7/1/2022		
Entyvio IV	vedolizumab IV	J3380	AR 2015011	4/1/2022		
Enzeevu	afilbercept-abzv	Q5149	AR 2024066	3/12/2025		Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Cimerli (Q5128), Eylea HD (J0177) or Eylea (J0178) preferred]
Epkinly	epcoritamab-bysp	J9321	AR 2023034	7/1/2023		
Epysqli	eculizumab-aagh	Q5151	AR 2016013	4/23/2025		Non-preferred [Soliris (J1299) preferred]
Erzofri	paliperidone palmitate	J2428	AR 2016021	3/19/2024		
Evenity	romosozumab-aqqg	J3111	AR 2019009	8/1/2019		
Evkeeza	evinacumab-dgnb	J1305	AR 2021027	4/1/2021		
Fabrazyme	agalsidase beta	J0180	AR 2023013	4/13/2023		
Flolan	epoprostenol	J1325	AR 1998144	1/1/2025		

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product
Fulphila	pegfilgrastim-jmdb	Q5108	AR 2021024	1/1/2024		Non-preferred [Neulasta (J2506) & Nyvepria (Q5122) preferred]
Fyarro	sirolimus protein-bound particles	J9331	AR 2022022	9/1/2022		
Fylnetra	pegfilgrastim-pbbk	Q5130	AR 2021024	1/1/2024		Non-preferred [Neulasta (J2506) & Nyvepria (Q5122) preferred]
Gamifant	emapalumab-lzsg	J9210	AR 2019013	11/1/2019		
Givlaari	givosiran	J0223	AR 2020009	4/1/2020		
Glassia	alpha-1 proteinase inhibitor human	J0257	AR 2017001	9/1/2023		
Grafapex	Treosulfan	C9175	AR 2025003	3/19/2025		
Granix	tbo-filgrastim	J1447	AR 2021024	1/1/2024		Non-preferred [Neivestym (Q5110) & Zarxio (Q5101) preferred]
Hemgenix	etranacogene dezaparvovec-drlb	J1411	AR 2023017	5/17/2023		
Herceptin	trastuzumab	J9355	AR 198158	1/1/2024		Non-preferred [Trazimera (Q5116), Ogivri (Q5114) & Ontruzant (Q5112) preferred]
Herceptin Hylecta	trastuzumab and hyaluronidase-oysk	J9356	AR 198158	1/1/2024		Non-preferred [Trazimera (Q5116), Ogivri (Q5114) & Ontruzant (Q5112) preferred]
Hercessi	trastuzumab-strf	Q5146	AR 198158	1/1/2025		Non-preferred [Trazimera (Q5116), Ogivri (Q5114) & Ontruzant (Q5112) preferred]
Herzuma	trastuzumab-pkrb	Q5113	AR 198158	1/1/2024		Non-preferred [Trazimera (Q5116), Ogivri (Q5114) & Ontruzant (Q5112) preferred]
Ilaris	canakinumab	J0638	AR 2020026	2/25/2021		
Ilumya	tildrakizumab-asmn	J3245	AR 2022048	4/1/2023		
Imdelltra	tarlatamab-dlle	J9026	AR 2024070	10/23/2024		

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product
Imlygic	talimogene laherparepvec	J9325	AR 2025015	5/28/2025		
Imuldosa	ustekinumab-srlf	Q5098	AR 2021028	5/1/2025		Non-preferred [Stelara IV (J3358) & Stelara SC (J3357) preferred]
Inflectra	infliximab-dyyb	Q5103	AR 1998161	4/1/2022		Preferred
Invega Sustenna	paliperidone palmitate	J2426	AR 2016021	4/1/2022		
Invega Trinza	paliperidone palmitate	J2427	AR 2016021	4/1/2022		
Istodax	romidepsin	J9319	AR 2021009	2/28/2024		
Ixifi	infliximab-qbtx	Q5109	AR 1998161	4/1/2022		Non-preferred [Inflectra (Q5103), Infliximab (J1745), Remicade (J1745) preferred]
Jemperli	dostarlimab	J9272	AR 2022008	2/21/2024		
Jevtana	cabazitaxel	J9043	AR 2021013	3/6/2024		
Kadcyla	ado-trastuzumab emtansine	J9354	AR 2013014	4/17/2024		
Kalbitor	ecallantide	J1290	AR 2013032	6/1/2018		
Kanjinti	trastuzumab-anns	Q5117	AR 198158	1/1/2024		Non-preferred [Trazimera (Q5116), Ogivri (Q5114) & Ontruzant (Q5112) preferred]
Kanuma	sebelipase alfa	J2840	AR 2023035	11/1/2023		
Kebilidi	eladocagene exuparvovec	J3590	AR 2025006	3/12/2025		
Kimmtrak	tebentafusp-tebn	J9274	AR 2022023	6/15/2022		
Kisunla	donanemab-azbt	J0175	AR 2024077	12/18/2024		
Krystexxa	pegloticase	J2507	AR 2018027	12/1/2018		
Kymriah	tisagenlecleucel	Q2042	AR 1998109	7/1/2018		
Kyprolis	carfilzomib	J9047	AR 2021003	2/7/2024		
Lamzede	velmanase alfa-tycv	J0217	AR 2023018	5/1/2023		
Lanreotide (Cipla)	lanreotide	J1932	AR 2023038	4/1/2025		
Lemtrada	alemtuzumab	J0202	AR 2016015	4/1/2018		
Lenmeldy	atidarsagene autotemcel	J3391	AR 2024043	8/28/2024		
Leqvio	inclisiran	J1306	AR 2022016	7/15/2022		
Leukine	sargramostim	J2820	AR 2021024	1/1/2024		
Lumizyme	alglucosidase alfa	J0221	AR 2020030	3/11/2021		

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product
Lunsumio	mosunetuzumab-axgb	J9350	AR 2023024	5/15/2023		
Lutathera	lutetium Lu 177 Dotatate	A9513	AR 2018014	5/1/2018		
Luxturna	voretigene neparvovec-rzyl	J3398	AR 2018021	2/15/2023		
Lyfgenia	lovotibeglogene autotemcel	J3394	AR 2024014	5/29/2024		
Mepsevii	vestronidase alfa-vjvk	J3397	AR 2018025	9/1/2018		
Monjuvi	tafasitamab-cxix	J9349	AR 2021005	6/1/2023		
Mvasi	bevacizumab-awwb	Q5107	AR 2017006 & AR 2023014	01/01/2024 - NOT PA'd for OPTHALMIC indications		Preferred
Naglazyme	galsulfase	J1458	AR 2018025	9/1/2018		
Neulasta	pegfilgrastim	J2506	AR 2021024	1/1/2024		Preferred
Neupogen	filgrastim	J1442	AR 2021024	1/1/2024		Non-preferred [Neivestym (Q5110) & Zarxio (Q5101) preferred]
Nexviazyme	avalglucosidase alfa-ngpt	J0219	AR 2021041	12/1/2021		
Niktimvo	axatilimab	J9038	AR 2025008	4/16/2025		
Nivestym	filgrastim-aafi	Q5110	AR 2021024	1/1/2024		Preferred
Nplate	romiplostim	J2802	AR 2008025	8/15/2023		
Nypozi	filgrastim-txid	Q5148	AR 2021024	1/1/2025		Non-preferred [Neivestym (Q5110) & Zarxio (Q5101) preferred]
Nyvepria	pegfilgrastim-apgf	Q5122	AR 2021024	1/1/2024		Preferred
Ocrevus	ocrelizumab	J2350	AR 2017021	4/15/2023		
Ocrevus Zunovo	ocrelizumab and hyaluronidase-ocsq	J2351	AR 2017021	1/22/2025		
Ogivri	trastuzumab-dkst	Q5114	AR 198158	1/1/2024		Preferred
OmvoH	mirikizumab-mrkz	J2267	AR 2024011	4/24/2024		
Oncaspar	pegaspargase	J9266	AR 2022019	8/1/2022		
Onivyde	irinotecan liposomal	J9205	AR 2021018	3/1/2024		
Onpattro	patisiran	J0222	AR 2022042	2/1/2023		
Ontruzant	trastuzumab-dttb	Q5112	AR 198158	1/1/2024		Preferred
Opdualag	nivolumab and relatlimab-rmbw	J9298	AR 2022038	10/1/2022		

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product
Opuviz	aflibercept-yszy	Q5153	AR 2024066	3/12/2025		Non-preferred [Vabysmo (J2777), Lucentis (J2778), Byooviz (Q5124), Cimerli (Q5128), Eylea HD (J0177) or Eylea (J0178) preferred]
Orencia	abatacept	J0129	AR 2006020	4/1/2022		
Otulfu IV and SC	ustekinumab-aaaz	Q9999	AR 2021028	3/5/2025		Non-preferred [Stelara IV (J3358) preferred]
Oxlumo	lumasiran	J0224	AR 2021032	9/15/2021		
Padcev	enfortumab vedotin-ejfv	J9177	AR 2021002	2/7/2024		
PiaSky	crovalimab-akkz	J1307	AR 2025001	1/15/2025		
Pluvicto	lutetium lu 177 vipivotide tetraxetan	A9607	AR 2022014	5/4/2022		
Pombiliti	cipaglucosidase alfa-atga	J1203	AR 2023051	12/19/2023		
Poteligeo	mogamulizumab-kpkc	J9204	AR 2022010	3/20/2024		
Prevymis IV	letermovir IV	J3490	AR 2018004	5/1/2024		
Prolastin	alpha-1 proteinase inhibitor human	J0256	AR 2017001	9/1/2023		
Pyzchiva IV	ustekinumab-ttwe	Q9997	AR 2021028	1/1/2025		Non-preferred [Stelara IV (J3358) preferred]
Pyzchiva SC	ustekinumab-ttwe	Q9996	AR 2021028	1/1/2025		Non-preferred [Stelara SC (J3357) preferred]
Qalsody	tofersen	J1304	AR 2023032	8/1/2023		
Radicava IV	edaravone IV	J1301	AR 2017026	12/1/2023		
Reblozyl	luspatercept-aamt	J0896	AR 2020006	3/1/2020		
Rebyota	fecal microbiota, live-jslm	J1440	AR 2023028	5/21/2023		
Releuko	filgrastim-ayow	Q5125	AR 2021024	1/1/2024		Non-preferred [Neivestym (Q5110) & Zarxio (Q5101) preferred]
Relizorb	digestive enzyme cartridge	B4105	AR 2017029	8/1/2017		
Remicade and Unbranded Infliximab	infliximab	J1745	AR 1998161	4/1/2022		Preferred
Remodulin	treprostinil IV	J3285	AR 1998144	1/1/2025		

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product
Renflexis	infliximab-abda	Q5104	AR 1998161	4/1/2022		Non-preferred [Inflectra (Q5103), Infliximab (J1745), Remicade (J1745) preferred]
Rethymic	allogeneic processed thymus tissue-agdc	J3590	AR 2022034	8/22/2022		
Revatio	sildenafil (IV)	J3490	AR 1998144	4/1/2022		
Revcovi	elapegademase-lvlr	J3590	AR 2024082	4/1/2025		
Riabni	rituximab-arrx	Q5123	AR 2021034 & AR 2006016		4/1/2022	x
Rituxan	rituximab	J9312	AR 2021034 & AR 2006016		4/1/2022	x
Rituxan Hycela	rituximab and hyaluronidase	J9311	AR 2021034 & AR 2006016		4/1/2022	x
Rivfloza	nedosiran	J3490	AR 2024017	6/5/2024		
Roctavian	valoctocogene roxaparvovec-rvox	J1412	AR 2023050	12/13/2023		
Rolvedon	eflapegrastim-xnst	J1449	AR 2021024	1/1/2024		Non-preferred [Neulasta (J2506) & Nyvepria (Q5122) preferred]
Ruconest	c1 esterase, inhibitor, recombinant	J0596	AR 2013032	6/1/2018		
Ruxience	rituximab-pvvr	Q5119	AR 2021034 & AR 2006016		4/1/2022	x
Rybrevant	amivantamab-vmjw	J9061	AR 2021040	3/1/2024		
Rylaze	asparaginase erwinia chrysanthemi (recombinant)- rywn	J9021	AR 2022019	8/1/2022		
Ryoncil	remestemcel-L-rknd	J3590	AR 2025019	6/18/2025		
Ryplazim	plasminogen, human-tvmh	J2998	AR 2022002	1/12/2022		
Rystiggo	rozanolixizumab-nol	J9333	AR 2024004	2/14/2024		
Rytelo	imetelstat	J0870	AR 2024080	12/11/2024		
Ryzneuta	efbemalenograstim alfa-vuxw	J9361	AR 2021024	7/1/2024		Non-preferred [Neulasta (J2506) & Nyvepria (Q5122) preferred]
Saphnelo	anifrolumab-fnia	J0491	AR 2022012	6/1/2022		

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product
Selarsdi	ustekinumab-aekn	Q9998	AR 2021028	1/1/2025		Non-preferred [Stelara IV (J3358) & Stelara SC (J3357) preferred]
Simponi Aria	golimumab	J1602	AR 2009015	4/1/2022		
Skyrizi IV	risankizumab-rzaa IV	J2327	AR 2022031	7/27/2022		
Skysona	elivaldogene autotemcel	J3590	AR 2023007	2/1/2023		
Soliris	eculizumab	J1299	AR 2016013	4/1/2018		Preferred
Somatuline depot	lanreotide	J1930	AR 2023038	12/1/2023		
Spevigo	spesolimab-sbzo	J1747	AR 2023002	1/1/2023		
Spinraza	nusinersen	J2326	AR 2019011	4/1/2018		
Stelara IV	ustekinumab	J3358	AR 2021028	9/1/2021		Preferred
Stelara SC	ustekinumab	J3357	AR 2021028	9/1/2021		Preferred
Steqeyma IV and SC	ustekinumab-stba	Q5099	AR 2021028	3/5/2025		Non-preferred [Stelara IV (J3358) preferred]
Stimufend	pegfilgrastim-fpgk	Q5127	AR 2021024	1/1/2024		Non-preferred [Neulasta (J2506) & Nyvepria (Q5122) preferred]
Susvimo	ranibizumab implant	J2779	AR 2010046	7/1/2022		
Talvey	talquetamab-tgvs	J3055	AR 2024007	3/6/2024		
Tecartus	brexucabtagene autoleucel	Q2053	AR 2024039	12/18/2020		
Tecelra	afamitresgene autoleucel	Q2057	AR 2024078	12/4/2024		
Tecvayli	teclistamab-cqyv	J9380	AR 2023015	4/19/2023		
Tepezza	teprotumumab-trbw	J3241	AR 2020004	3/23/2020		
Tivdak	tisotumab vedotin-tftv	J9273	AR 2022025	10/1/2022		
Tofidence	tocilizumab-bavi	Q5133	AR 2020022	5/15/2024		
Trazimera	trastuzumab-qyyp	Q5116	AR 198158	1/1/2024		Preferred
Tremfya IV	guselkumab IV	J1628	AR 2024071	10/23/2024		
Trodelvy	sacituzumab govitecan-hziy	J9317	AR 2020020	2/1/2023		
Truxima	rituximab-abbs	Q5115	AR 2021034 & AR 2006016		4/1/2022	x
Tyenne IV	tocilizumab-aaqg IV	Q5135	AR 2020022	7/1/2024		
Tyruko	natalizumab-sztn	Q5134	AR 2016018	12/1/2025		
Tysabri	natalizumab	J2323	AR 2016018	4/1/2022		
Tzield	teplizumab-mzwv	J9381	AR 2023012	4/19/2023		

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product
Udenyca	pegfilgrastim-cbqv	Q5111	AR 2021024	1/1/2024		Non-preferred [Neulasta (J2506) & Nyvepria (Q5122) preferred]
Ultomiris	ravulizumab-cwyz	J1303	AR 2016013	2/1/2019		
Unloxcyt	cosibelimab ipdl	J9275	AR 2025017	6/4/2025		
Uplizna	inebilizumab-cdon	J1823	AR 2020016	7/1/2020		
Uptravi IV	selexipag IV	J3490	AR 1998144	1/1/2025		
Vegzelma	bevacizumab-adcd	Q5129	AR 2017006 & AR 2023014	01/01/2024 - NOT PA'd for OPHTHALMIC indications		Non-preferred [Mvasi (Q5107) & Zirabev (Q5118) preferred]
Velettri	epoprostenol	J1325	AR 1998144	1/1/2025		
Veopoz	pozelimab-bbfg	J9376	AR 2024002	2/1/2024		
Vimizim	elosulfase alfa	J1322	AR 2018025	9/1/2018		
Vpriv	velaglucerase alfa	J3385	AR 2023048	2/1/2024		
Vyepti	eptinezumab-jjmr	J3032	AR 2020007	4/1/2022		
Vyjuvek	beremagene geperpavec-svdt	J3401	AR 2023047	12/13/2023		
Vyloy	zolbetuximab	J1326	AR 2025005	2/26/2025		
Vyvgart	efgartigimod alfa-fcab	J9332	AR 2022001	1/12/2022		
Vyvgart Hytrulo	efgartigimod alfa and hyaluronidase-qvfc	J9334	AR 2024063	1/29/2025		
Wezlana IV	ustekinumab-auub	Q5138	AR 2021028	7/1/2024		Non-preferred [Stelara IV (J3358) preferred]
Wezlana SC	ustekinumab-auub	Q5137	AR 2021028	7/1/2024		Non-preferred [Stelara SC (J3357) preferred]
Xenpozyme	olipudase alfa-rpcp	J0218	AR 2023008	2/1/2023		
Xeomin	incobotulinumtoxin a	J0588	AR 2018002	4/1/2022		
Xiaflex	clostrisidial collagenase	J0775	AR 2010013	8/1/2023		
Ycanth	cantharidin	J7354	AR 2024012	5/15/2024		
Yescarta	axicabtagene ciloleucel	Q2041	AR 2024038	7/1/2018		
Yesintek IV and SC	ustekinumab-kfce	Q5100	AR 2021028	3/5/2025		Non-preferred [Stelara IV (J3358) preferred]
Zarxio	filgrastim-sndz	Q5101	AR 2021024	1/1/2024		Preferred
Zemaira	alpha-1 proteinase inhibitor (human)	J0256	AR 2017001	9/1/2023		
Zepzelca	lurbinectedin	J9223	AR 2021001	7/1/2023		

Brand Name	Generic Name	HCPCS	AR Policy	AR Policy Effective Date	End Prior Approval Date	2025 Preferred Product
Ziextenzo	pegfilgrastim-bmez	Q5120	AR 2021024	1/1/2024		Non-preferred [Neulasta (J2506) & Nyvepria (Q5122) preferred]
Ziihera	zanidatamab-hrii	J9276	AR 2025002	2/12/2025		
Zirabev	bevacizumab-bvzr	Q5118	AR 2017006 & AR 2023014	01/01/2024 - NOT PA'd for OPHTHALMIC indications		Preferred
Zolgensma	onasemnogene abeparvovec-xioi	J3399	AR 2019011	8/1/2019		
Zulresso	brexanolone	J1632	AR 2019012	8/15/2019		
Zynlonta	loncastuximab tesirine-lpyl	J9359	AR 2022010	3/20/2024		
Zynteglo	betibeglogene autotemcel	J3393	AR 2022046	11/1/2022		